FDA recall record

Aceto US a.) Actylis brand Lithium Orotate 4% packaged in HDPE Liner in recall — FDA H-0441-2025

4% Lithium Orotate product may only contain 3% and 9% Lithium Orotate product may contain 4.45%

Class IIIclassification
H-0441-2025official record ID
Aug 20, 2025report date

Recall record at a glance

Official recordH-0441-2025
CategoryFood Recalls
ClassificationClass III
FDA record statusTerminated
Recalling firmAceto US, L.L.C
Report dateAug 20, 2025
Recall initiation dateJun 24, 2025
Quantity9%: 6033.45 Kg; 4%: 4485.95 Kg
LocationPort Washington, NY, United States

Official product description

a.) Actylis brand Lithium Orotate 4% packaged in HDPE Liner in a 25kg carton b.) Actylis brand Lithium Orotate 9% packaged in HDPE Liner in a 25kg carton

Why the product was recalled

4% Lithium Orotate product may only contain 3% and 9% Lithium Orotate product may contain 4.45%

Distribution information

NJ, NC, CA, UT, MT, FL, AZ, NC, NY

How to read the classification

FDA Class III generally covers situations in which use of or exposure to the product is not likely to cause adverse health consequences. The classification displayed here is taken from the FDA enforcement record.

Additional record details

Recall type: Voluntary: Firm initiated. Initial notification: E-Mail.

What to do next

If you believe you have the recalled product, use the recall number and firm information above to confirm the official notice and follow the instructions issued by the FDA, recalling firm, retailer or product manufacturer. For drugs and medical devices, decisions about treatment or medical care should be discussed with a qualified health professional.

About this record

Recall Lookup USA preserves the most complete source information successfully retrieved. We do not create missing facts or infer affected lots or VINs. The official record may still change, so use the identifier above when verifying current instructions.

FDA source limitation: openFDA enforcement reports are a reference dataset, not a live public-alert or recall-lifecycle service. FDA notes that enforcement-report status may not be updated after classification. Confirm current actions with the FDA, recalling firm or appropriate healthcare professional when relevant.